Senior/Executive Director, Biotransformation and Drug-Drug Interaction
This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
About The Position
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. Disc Medicine values collaboration, professional development, and scientific integrity and promotes an inclusive company culture that empowers and inspires. The Early Development and Clinical Pharmacology (EDCP) group at Disc Medicine seeks a scientific expert in biotransformation and drug-drug interaction (DDI) evaluation areas. The successful candidate will provide biotransformation and DDI evaluation strategy and execution to support drug discovery, nonclinical development, and clinical development. This includes designing in vitro metabolic enzyme and transporter-related studies, drug-drug interaction risk evaluation, and clinical DDI evaluations via clinical studies and/or PBPK modeling. This person is expected to interact with cross-functional teams providing biotransformation, DDI evaluation, and other scientific inputs. The successful candidate will also provide biotransformation-related strategy and support to achieve program milestones, including IND, IB, and NDA submissions. The candidate should have expertise in biotransformation, transporter, and drug-drug interaction areas and comprehensive knowledge of best regulatory practices and experimental methodology.
